SCHEMBL82458

SCHEMBL82458

C=C(C)C(=O)NCCCNC(=O)c1ccc(C(=O)c2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.55
RAB9A P51151 5/20 0.55
NAAA Q02083 1/20 0.54
LMNA P02545 2/20 0.53
POLB P06746 1/20 0.53
HPGD P15428 2/20 0.52
ALDH1A1 P00352 2/20 0.52
HDAC3 O15379 2/20 0.50
HDAC4 P56524 2/20 0.50
HDAC1 Q13547 2/20 0.50
HDAC7 Q8WUI4 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC10 Q969S8 2/20 0.50
HDAC11 Q96DB2 2/20 0.50
HDAC8 Q9BY41 2/20 0.50
HDAC6 Q9UBN7 2/20 0.50
HDAC9 Q9UKV0 2/20 0.50
HDAC5 Q9UQL6 2/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25341219 0.95 NPC1 (0.50) NPC1RAB9ANAAALMNAPOLB
SCHEMBL6135253 0.94 NPC1 (0.61) NPC1RAB9ANAAALMNAPOLB
SCHEMBL15768755 0.92 LMNA (0.49) NPC1RAB9ANAAALMNAPOLB
SCHEMBL15768756 0.92 LMNA (0.49) NPC1RAB9ANAAALMNAPOLB
SCHEMBL28063078 0.91 NAAA (0.64) NPC1RAB9ANAAALMNAPOLB
SCHEMBL31174260 0.91 SMN1; SMN2 (0.55) NPC1RAB9ANAAAPOLBHPGD
SCHEMBL16670767 0.91 SMN1; SMN2 (0.55) NPC1RAB9ANAAAPOLBHPGD
SCHEMBL20025770 0.89 NAAA (0.54) NPC1RAB9ANAAALMNAPOLB
SCHEMBL28530862 0.88 TSHR (0.48) NPC1RAB9ANAAALMNAPOLB
SCHEMBL22373760 0.88 LMNA (0.62) NPC1RAB9ANAAALMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 612 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12605695-B2 Molecularly imprinted fluorescent polymers for direct detection of glyphosate, its degradation products, and metabolites BUNDESREPUBLIK DEUTSCHLAND, VERTRETEN DURCH DEN BUNDESMINISTER FÜR WIRTSCHAFT UND ENERGIE, DIESER VERTRETEN DURCH DEN PRÄSIDENTEN DER BUNDESANSTALT FÜR MATERIALFORSCHUNG UND -PRÜFUNG, (BAM) (DE) 2026-04-21 US claimed
US-20260098225-A1 POLYACRYLIC ACID CONTAINING LUBRICIOUS COATINGS FOR MEDICAL DEVICES WITH ENHANCED PROPERTIES SURMODICS INC (US) 2026-04-09 US claimed
WO-2025198684-A9 BaTiO3 NANOCRYSTALS AND NANOCOMPOSITES PIXELLIGENT TECHNOLOGIES LLC (US) 2025-11-27 WO claimed
EP-4615530-A1 POLYACRYLIC ACID CONTAINING LUBRICIOUS COATINGS FOR MEDICAL DEVICES WITH ENHANCED PROPERTIES SurModics, Inc. (US) 2025-09-17 EP claimed
US-20250230334-A1 SOLVENT-FREE FORMULATIONS AND NANOCOMPOSITES PT SPE SUBCO LLC (US) 2025-07-17 US claimed
CN-120114655-A Delivery of hydrophobic active agent particles 苏尔莫迪克斯公司 2025-06-10 CN claimed
EP-3042645-B2 Dental composites with improved storage stability IVOCLAR VIVADENT AG (LI) 2025-03-12 EP claimed
EP-4514346-A1 MEDICAL DEVICE COATINGS WITH MICROCRYSTALLINE ACTIVE AGENTS SurModics, Inc. (US) 2025-03-05 EP claimed
EP-4489804-A1 THROMBORESISTANT COATINGS, COATED DEVICES, AND METHODS Surmodics Coatings, LLC (US) 2025-01-15 EP claimed
US-20240342345-A1 LUBRICIOUS MEDICAL DEVICE COATING WITH LOW PARTICULATES BANK OF MONTREAL, AS COLLATERAL AGENT 2024-10-17 US claimed
US-20030099949-A1 Arrays having clustered arrangements and methods of making and using SURMODICS, INC. 2003-05-29 US claimed
EP-1309360-A2 MEDICAMENT INCORPORATION MATRIX SurModics, Inc. (US) 2003-05-14 EP claimed
WO-2003031054-A2 ARRAYS HAVING CLUSTERED ARRANGEMENTS AND METHODS OF MAKING AND USING THEM SURMODICS, INC. (US) 2003-04-17 WO claimed
US-20030073086-A1 Randomly ordered arrays and methods of making and using SURMODICS, INC. 2003-04-17 US claimed
WO-2003031979-A1 RANDOMLY ORDERED ARRAYS AND METHODS OF MAKING AND USING SURMODICS, INC. (US) 2003-04-17 WO claimed
US-6506895-B2 Oligonucleotide for use in generation of nucleic acid chips SURMODICS, INC. 2003-01-14 US claimed
US-20020041899-A1 Medicament incorporation matrix Surmodics Coatings, LLC 2002-04-11 US claimed
WO-2002013871-A2 MEDICAMENT INCORPORATION MATRIX SURMODICS, INC. (US) 2002-02-21 WO claimed
EP-1069916-A2 LATENT REACTIVE BLOOD COMPATIBLE AGENTS SurModics, Inc. (US) 2001-01-24 EP claimed
WO-1999047176-A2 LATENT REACTIVE BLOOD COMPATIBLE AGENTS SURMODICS, INC. (US) 1999-09-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12605695-B2 Molecularly imprinted fluorescent polymers for direct detection of glyphosate, its degradation products, and metabolites GRIN3A, PAM, GYPA NPC1 3549/4885RAB9A 3423/4885NAAA 175/4885
US-20260098225-A1 POLYACRYLIC ACID CONTAINING LUBRICIOUS COATINGS FOR MEDICAL DEVICES WITH ENHANCED PROPERTIES CUTA, EED, SELP NPC1 4807/4885RAB9A 3018/4885NAAA 2045/4885
US-20020041899-A1 Medicament incorporation matrix COL14A1, MATR3, ECPAS NPC1 4799/4885RAB9A 4877/4885NAAA 1455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.